<DOC>
	<DOCNO>NCT02385084</DOCNO>
	<brief_summary>The purpose study measure much new LY2409021 tablet formulation get blood stream long take body get rid , compare current LY2409021 capsule formulation . In addition , safety tolerability new current formulation evaluate . Information side effect may occur also collect . The study two part . Each participant may enroll one part . The study last 8 week participant . Screening required prior start study .</brief_summary>
	<brief_title>A Study LY2409021 Formulations Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Overtly healthy male surgically sterile postmenopausal female , determine medical history physical examination Have body mass index ( BMI ) 18.0 32.0 kilogram per square meter ( kg/m^2 ) Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have know allergy LY2409021 , related compound component formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have know ongoing psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>